An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...
How Genetic Factors Are Associated with Behavioral Side Effects of GLP-1 Weight Loss Medication Glucagon-like peptide 1 ...
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
The pharmaceutical industry came up with medicine that stops people from craving processed, addictive foods and the food industry is in a panic.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback